

AssayMax™ Human Ferritin ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μl of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 15 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

AssayMax™ Human Ferritin ELISA Kit

Catalog No. EF2003-1
Sample insert for reference use only

Introduction

Ferritin is an iron storage protein. It consists of 24 subunits with a combined molecular weight of 474 kDa. Serum ferritin level is related to body iron stores and is influenced by several diseases. High ferritin serum levels are associated with iron overload (1), diabetes mellitus (2), adult-onset Still's disease (AOSD) [3], excessive macrophage activation (4), and alcohol intake (5). On the other hand, a low level of ferritin is an indication of iron deficiency anemia (6).

Principle of the Assay

The AssayMax™ Human Ferritin ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of ferritin in human plasma, serum, milk, and CSF samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human ferritin in approximately 4 hours. A polyclonal antibody specific for human ferritin has been pre-coated onto a 96-well microplate with removable strips. Ferritin in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human ferritin, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Ferritin Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human ferritin.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Ferritin Standard: Human ferritin in a buffered protein base, calibrated against WHO International Standard (40 ng, lyophilized).
- **Biotinylated Human Ferritin Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against human ferritin (120 µl).
- EIA Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (20 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

 Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 10-fold sample dilution is suggested into EIA Diluent;

- however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 10-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Milk: Collect milk using sample tube. Centrifuge samples at 800 x g for 10 minutes. The sample is suggested for use at 1x or within the range of 2x 10x into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- CSF: Collect cerebrospinal fluid (CSF) using sample pot. Centrifuge samples at 3000 x g for 10 minutes. A 4-fold sample dilution is suggested into EIA Diluent or within the range of 1x 10x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)					
	100x		10000x			
A)	4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl.	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.			
	1000x		100000x			
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution Assuming the needed volume is less than or equal to 240 μl.	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution Assuming the needed volume is less than or equal to 240 μl.			

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** Dilute the EIA Diluent Concentrate 10-fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Ferritin Standard: Reconstitute the Human Ferritin Standard (40 ng) with 0.8 ml of EIA Diluent to generate a 50 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (50 ng/ml) 2-fold with equal volume of EIA Diluent to produce 25, 12.5, 6.25, 3.125, 1.563, and 0.781 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 30 days.

Standard Point	Dilution	[Ferritin] (ng/ml)
P1	1 part Standard (50 ng/ml)	50
P2	1 part P1 + 1 part EIA Diluent	25
P3	1 part P2 + 1 part EIA Diluent	12.5
P4	1 part P3 + 1 part EIA Diluent	6.25
P5	1 part P4 + 1 part EIA Diluent	3.125
P6	1 part P5 + 1 part EIA Diluent	1.563
P7	1 part P6 + 1 part EIA Diluent	0.781
P8	EIA Diluent	0.0

- Biotinylated Human Ferritin Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the
 desired amount of the conjugate 100-fold with EIA Diluent to produce a
 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human Ferritin Standard or sample to each well. Gently tap
 plate to thoroughly coat the wells. Break any bubbles that may have
 formed. Cover wells with a sealing tape and incubate for 2 hours. Start
 the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 μl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 μl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Ferritin Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 15 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	50	2.327	2.340
L T	30	2.353	2.540
P2	25	1.784	1.815
12	23	1.846	1.015
Р3	12.5	1.235	1.198
13	12.5	1.161	1.150
P4	6.25	0.708	0.718
1 7	0.23	0.728	0.710
P5	3.125	0.426	0.412
13		0.398	0.412
P6	1.563	0.256	0.264
	1.505	0.272	0.201
P7	0.781	0.180	0.186
. ,	0.701	0.192	0.100
P8	0.0	0.123	0.119
	0.0	0.115	0.113
Sample: Poo	oled Normal	0.359	0.376
Sodium Citrate	e Plasma (10x)	0.393	0.376
Sample: Poo	oled Normal	0.519	0.403
Serum		0.467	0.493

Standard Curve

 The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human Ferritin Standard Curve



Reference Value

- Normal human ferritin plasma and serum levels range from 11 – 336 ng/ml.
- Plasma and serum samples from healthy adults were tested (n=40). On average, human ferritin level was 31 ng/ml.

Sample	n	Average Value (ng/ml)
Pooled Normal Plasma	10	28.0
Normal Plasma	20	25.3
Pooled Normal Serum	10	39.7

Performance Characteristics

- Kit standard has been calibrated against WHO International Standard.
- This assay recognizes both natural and recombinant human ferritin.
- The minimum detectable dose of human ferritin as calculated by 2SD from the mean of a zero standard was established to be 0.5 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Prec	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	6.7%	5.4%	5.3%	10.9%	10.1%	9.1%
Average CV (%)	5.8%				10.0%	

Spiking Recovery

 Recovery was determined by spiking two plasma samples with different ferritin concentrations.

Sample	Unspiked Sample (ng/ml)	Spiking Value (ng/ml)	Expected	Observed	Recovery (%)
	3.0	3.0	6.0	5.7	95%
1		6.0	9.0	8.2	91%
		12.0	15.0	14.7	98%
	6.2	3.0	9.2	8.9	97%
2		6.0	12.2	11.6	95%
		12.0	18.2	16.5	91%
Average Recovery (%)					95%

Linearity

• Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)					
Sample Dilution Plasma Serum					
5x	92%	91%			
10x	99%	101%			
20x	106%	105%			

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Equine	None
Monkey	100%
Mouse	None
Rat	None
Swine	10%
Rabbit	None

Troubleshooting

Issue	Causes	Course of Action
	Use of improper	Check the expiration date listed before use.
	components	 Do not interchange components from different lots.
		 Check that the correct wash buffer is being used.
		 Check that all wells are empty after aspiration.
	Improper wash step	 Check that the microplate washer is dispensing properly.
		 If washing by pipette, check for proper pipetting
_		technique.
Low Precision	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
re	Inconsistent volumes	 Pipette properly in a controlled and careful manner.
>	loaded into wells	 Check pipette calibration.
ò	loaded lifto wells	 Check pipette for proper performance.
	Insufficient mixing of	 Thoroughly agitate the lyophilized components after
	reagent dilutions	reconstitution.
	reagent anations	Thoroughly mix dilutions.
		 Check the microplate pouch for proper sealing.
	Improperly sealed	 Check that the microplate pouch has no punctures.
	microplate	Check that three desiccants are inside the microplate
		pouch prior to sealing.
_	Microplate was left	Each step of the procedure should be performed
na	unattended between	uninterrupted.
ig	steps	
h S	Omission of step	Consult the provided procedure for complete list of steps.
Unexpectedly Low or High Signal Intensity	Steps performed in incorrect order	 Consult the provided procedure for the correct order.
5 ≥	Insufficient amount of	Check pipette calibration.
w o	reagents added to	Check pipette for proper performance.
ly Low o	wells	
ੂੰ ≦ੂ	Wash step was skipped	 Consult the provided procedure for all wash steps.
je d	Improper wash buffer	 Check that the correct wash buffer is being used.
ect	Improper reagent	 Consult reagent preparation section for the correct
х	preparation	dilutions of all reagents.
ne	Insufficient or	 Consult the provided procedure for correct incubation
-	prolonged incubation	time.
	periods	
		Sandwich ELISA: If samples generate OD values higher
#:		than the highest standard point (P1), dilute samples
ė	Non ontimal cample	further and repeat the assay.
_ ≧	Non-optimal sample dilution	 Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples
บี	ullution	further and repeat the assay.
5		User should determine the optimal dilution factor for
da		samples.
Deficient Standard Curve Fit	Contamination of	A new tip must be used for each addition of different
St	reagents	samples or reagents during the assay procedure.
int .	Contents of wells	Verify that the sealing film is firmly in place before placing
icie	evaporate	the assay in the incubator or at room temperature.
efi		Pipette properly in a controlled and careful manner.
Δ	Improper pipetting	Check pipette calibration.
	, , , , ,	Check pipette for proper performance.
	proper pipetting	

Insufficient mixing or reagent dilutions	Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
------------------------------------------	------------------------------------------------------------------------------------------------

References

- (1) Solis-Herruzo JA. (2003) Rev Esp Enferm Dig. 95(5):351-7, 343-50.
- (2) Canturk Z et al. (2003) Endocr Res. 29(3):299-306.
- (3) Omagari K et al. (2003) Am J Med Sci. 326(3):148-51.
- (4) Lambotte O et al. (2003) J Rheumatol. 30(5):1027-8.
- (5) Whitfield JB et al. (2001) Alcohol Clin Exp Res. 25(7):1037-45.
- (6) Eskeland B et al. (1999) Acta Paediatr. 88(8):815-21.

Version 6.7R